Drug intelligence / Profile preview

TML-FIR-19

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Small Molecules
Administration: Oral

Overview

TML-FIR-19 is a preclinical-stage nonsystemic antibiotic candidate being developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) specifically engineered for targeted delivery to the colon via oral administration. By concentrating the antibiotic's activity within the colon and minimizing systemic absorption, TML-FIR-19 is designed to treat localized gastrointestinal conditions or infections while reducing the risk of systemic side effects and preserving the non-target systemic microbiome.

Beyond the preview

Go deeper on TML-FIR-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-FIR-19.

Explore the full profile